Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Operating Margin % is 7.25% as of Mar. 2026, which is 67% below its 10-year median of 22.29. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 87.13% on this metric.
The historical rank and industry rank for Invicta Diagnostic's Operating Margin % or its related term are showing as below:
NSE:INVICTA'
s Operating Margin % Range Over the Past 10 Years
Min: 20.14 Med: 22.29 Max: 32.74
Current: 20.14
NSE:INVICTA's Operating Margin % is ranked better than 87.13% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.88
vs NSE:INVICTA: 20.14
Invicta Diagnostic's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Invicta Diagnostic Operating Margin % Related Terms
Invicta Diagnostic Operating Margin % Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Operating Margin % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Operating Margin %
32.74
22.29
20.14
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Operating Margin %
0.00
0.00
31.86
7.25
NSE:INVICTA vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Invicta Diagnostic's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Operating Margin % of 7.25% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Invicta Diagnostic and its competitors. This is 67% below median its historical median of 22.29. Over the past decade, Invicta Diagnostic's Operating Margin % has ranged from 20.14 to 32.74. According to the industry distribution chart, Invicta Diagnostic ranks #26 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 12.9%.
Is Invicta Diagnostic's Operating Margin % too high?
Invicta Diagnostic's current Operating Margin % of 7.25% is 67% below median its 10-year median of 22.29. Over the past 10 years, this metric has ranged from a low of 20.14 to a high of 32.74. Based on the distribution chart, Invicta Diagnostic ranks #26 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #26 out of 202 companies for Operating Margin %. This places Invicta Diagnostic in the top 13% of its industry — outperforming the majority of peers. Historically, Invicta Diagnostic's own Operating Margin % has ranged from 20.14 to 32.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current Operating Margin % is 7.25%, which is 67% below median its own 10-year median of 22.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Operating Margin % of 7.25%. The current Operating Margin % is 7.25%, which is 67% below median its 10-year median of 22.29. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Operating Margin % is 7.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
